United States
Ethos Biosciences is a healthcare innovation company that focuses on designing, developing, and manufacturing accurate, repeatable, and easy-to-use diagnostics. Established in 2018 as a subsidiary of Ott Scientific, the company aims to drive healthcare innovation by providing diagnostic tools for scientists and practitioners. Notably, in November 2018, Ethos Biosciences expanded its portfolio by acquiring the Exocell diagnostic operation in Philadelphia from Glycadia Pharmaceuticals, enhancing its capabilities in the healthcare industry.
The acquisition of Exocell, founded in 1988 by Dr. Margo Cohen, MD/PhD, is significant as it enabled Ethos Biosciences to delve into diagnostic and therapeutic solutions for diabetes. With a pioneering presence in nephrology diagnostics, Exocell boasts 15 patents and over 2000 research citations, continuing to serve top research, academic, and industrial institutions around the globe.
It's important to note that Ott Scientific is a family-owned and operated group specializing in healthcare and manufacturing, with expertise in monomers, polymers, microspheres, and reagents for the pharmaceutical, medical device, and diagnostic industries.
While specific information regarding the latest investment and investors is currently unavailable, Ethos Biosciences' strategic moves and partnerships position it as a promising player in the healthcare and manufacturing industries, showcasing potential for further growth and innovation in the coming years.
